Pacira (PCRX) Director Samit Hirawat Receives Equity Awards

What Happened
Samit Hirawat, a director of Pacira BioSciences (PCRX), was granted two equity awards on 2026-06-10: 6,405 restricted stock units (RSUs) and a derivative award covering 10,891 shares (stock option). Both grants show an acquisition price of $0 (typical for awards) and therefore have no immediate cash value reported in the Form 4.

Key Details

• Transaction date: 2026-06-10; Form 4 filed 2026-06-12 (filed within the common 2-business-day window).
• Award amounts: 6,405 RSUs; 10,891-share stock option award. Reported price: $0 (grant).
• Vesting: Both awards vest on June 10, 2027, contingent on the reporting person remaining in continuous service.
• RSU detail: Each RSU represents the contingent right to receive one share upon vesting (Footnote F1).
• Option detail: The stock option vests and becomes exercisable on June 10, 2027 (Footnote F2). Strike/exercise price and post-transaction total holdings were not provided in the excerpt.

Context
These are forward-looking equity awards, not open-market purchases or immediate sales. Awards that vest over time are common compensation tools for directors and do not indicate an immediate buy or sell signal; they only convert into exercisable shares or stock on the stated vesting date if the service condition is met.